Literature DB >> 23867487

Description of outbreaks of health-care-associated infections related to compounding pharmacies, 2000-12.

Catherine Staes1, Jason Jacobs, Jeanmarie Mayer, Jill Allen.   

Abstract

PURPOSE: Outbreaks of health-care-associated infections related to compounding pharmacies from 2000 through 2012 are described.
METHODS: PubMed and the websites for the Centers for Disease Control and Prevention and the Food and Drug Administration were searched to identify infectious outbreaks associated with compounding pharmacies outside the hospital setting between January 2000 and November 2012.
RESULTS: Between January 2000 and before the 2012 fungal meningitis outbreak, 11 outbreaks were identified, involving 207 infected patients and 17 deaths after exposure to contaminated compounded drugs. The 2012 meningitis outbreak had a similar mortality rate but increased these totals almost fivefold. Half of the outbreaks involved patients in more than one state. Three outbreaks involved ophthalmic drugs. The remaining outbreaks involved corticosteroids, heparin flush solutions, cardioplegia solution, i.v. magnesium sulfate, total parenteral nutrition, and fentanyl. The outbreaks were caused by pathogens commonly associated with health-care-associated infections, common skin commensals, and organisms that rarely cause infection. Morbidity was substantial, including vision loss. Half the outbreaks resulted in recall of all sterile drugs from the pharmacy due to systemic problems with sterile procedures.
CONCLUSION: Before the nationwide 2012 fungal meningitis outbreak, drugs produced by compounding pharmacies were associated with 11 other smaller, but equally serious, outbreaks that occurred sporadically over the past 12 years. Lapses in sterile compounding procedures led to contamination of compounded drugs, exposure to patients, and a threat to public health in these outbreaks. Recognition and subsequent public health investigation were usually triggered by the occurrence of illness among multiple patients in a single health care setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23867487      PMCID: PMC3886339          DOI: 10.2146/ajhp130049

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  29 in total

1.  Mandatory reporting of diseases and conditions by health care professionals and laboratories.

Authors:  S Roush; G Birkhead; D Koo; A Cobb; D Fleming
Journal:  JAMA       Date:  1999-07-14       Impact factor: 56.272

2.  Multistate fungal meningitis outbreak -- interim guidance for treatment.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-10-19       Impact factor: 17.586

3.  Avastin doesn't blind people, people blind people.

Authors:  Serafin Gonzalez; Philip J Rosenfeld; Michael W Stewart; Jennifer Brown; Steven P Murphy
Journal:  Am J Ophthalmol       Date:  2012-02       Impact factor: 5.258

4.  Sodium tetradecyl sulfate for sclerotherapy treatment of veins: is compounding pharmacy solution safe?

Authors:  Mitchel P Goldman
Journal:  Dermatol Surg       Date:  2004-12       Impact factor: 3.398

5.  An outbreak of postoperative gram-negative bacterial endophthalmitis associated with contaminated trypan blue ophthalmic solution.

Authors:  Rebecca Sunenshine; Maureen Schultz; Mary G Lawrence; Soo Shin; Bette Jensen; Sabiha Zubairi; Ann M Labriola; Alicia Shams; Judith Noble-Wang; Matthew J Arduino; Fred Gordin; Arjun Srinivasan
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

6.  A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy.

Authors:  Rebecca H Sunenshine; Esther T Tan; Dawn M Terashita; Bette J Jensen; Marilyn A Kacica; Emily E Sickbert-Bennett; Judith A Noble-Wang; Michael J Palmieri; Dianna J Bopp; Daniel B Jernigan; Sophia Kazakova; Eddy A Bresnitz; Christina G Tan; L Clifford McDonald
Journal:  Clin Infect Dis       Date:  2007-07-24       Impact factor: 9.079

7.  Deaths from intravenous colchicine resulting from a compounding pharmacy error--Oregon and Washington, 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-10-12       Impact factor: 17.586

8.  Quality investigation of hydroxyprogesterone caproate active pharmaceutical ingredient and injection.

Authors:  John L Chollet; Michael J Jozwiakowski
Journal:  Drug Dev Ind Pharm       Date:  2012-02-13       Impact factor: 3.225

9.  Sphingomonas paucimobilis bloodstream infections associated with contaminated intravenous fentanyl.

Authors:  Lisa L Maragakis; Romanee Chaiwarith; Arjun Srinivasan; Francesca J Torriani; Edina Avdic; Andrew Lee; Tracy R Ross; Karen C Carroll; Trish M Perl
Journal:  Emerg Infect Dis       Date:  2009-01       Impact factor: 6.883

10.  Pharmacy compounding primer for physicians: prescriber beware.

Authors:  Sarah Sellers; Wulf H Utian
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546

View more
  12 in total

Review 1.  Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks.

Authors:  Kaitlin Benedict; Malcolm Richardson; Snigdha Vallabhaneni; Brendan R Jackson; Tom Chiller
Journal:  Lancet Infect Dis       Date:  2017-07-31       Impact factor: 25.071

Review 2.  U.S. Compounding Pharmacy-Related Outbreaks, 2001-2013: Public Health and Patient Safety Lessons Learned.

Authors:  Nadine Shehab; Megan N Brown; Alexander J Kallen; Joseph F Perz
Journal:  J Patient Saf       Date:  2018-09       Impact factor: 2.844

3.  Should Hospital Pharmacies That Are Not Fully Compliant with USP General Chapter <797> Standards Outsource, to the Fullest Extent Possible, the Preparation of Compounded Sterile Products to a Facility That Is Compliant?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2014-11

Review 4.  Fungi associated with drug recalls and rare disease outbreaks.

Authors:  Donald G Ahearn; R Doyle Stulting
Journal:  J Ind Microbiol Biotechnol       Date:  2014-08-31       Impact factor: 3.346

5.  Mining social media data to assess the risk of skin and soft tissue infections from allergen immunotherapy.

Authors:  Kimberly G Blumenthal; Maxim Topaz; Li Zhou; Tyler Harkness; Roee Sa'adon; Ofrit Bar-Bachar; Aidan A Long
Journal:  J Allergy Clin Immunol       Date:  2019-02-02       Impact factor: 10.793

6.  Patient Safety Incidents Related to the Use of Parenteral Nutrition in All Patient Groups: A Systematic Scoping Review.

Authors:  Priya Mistry; Rebecca Heather Smith; Andy Fox
Journal:  Drug Saf       Date:  2021-12-21       Impact factor: 5.606

7.  Retention of Sterile Compounding Knowledge Among Pharmacy Technicians.

Authors:  Jameda Davis; Candace Ayars
Journal:  J Pharm Technol       Date:  2021-07-20

8.  Seven cases of probable endotoxin poisoning related to contaminated glutathione infusions.

Authors:  T Johnstone; E Quinn; S Tobin; R Davis; Z Najjar; B Battye; L Gupta
Journal:  Epidemiol Infect       Date:  2018-04-20       Impact factor: 2.451

Review 9.  Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.

Authors:  JoAnn V Pinkerton; James H Pickar
Journal:  Menopause       Date:  2016-02       Impact factor: 2.953

Review 10.  Pharmaceutical Compounding: a History, Regulatory Overview, and Systematic Review of Compounding Errors.

Authors:  C James Watson; James D Whitledge; Alicia M Siani; Michele M Burns
Journal:  J Med Toxicol       Date:  2020-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.